Abbott Vascular's Xience V Shows Sustained Benefit in Women at 3 Years in SPIRIT III
February 8, 2011—Vivian G. Ng, MD, et al published 3-year follow-up data from the SPIRIT III trial online ahead of print in the American Journal of Cardiology. The investigators found that the Xience V everolimus-eluting stent (Abbott Vascular, Santa Clara, CA) demonstrated improved clinical outcomes compared to the Taxus Express2 paclitaxel-eluting stent (Boston Scientific Corporation, Natick, MA). Gregg W. Stone, MD, is principal investigator of SPIRIT III, which is sponsored by Abbott Vascular.
